Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional Results available

Effect of Intranasal Insulin on LH Concentrations in Man

NCT02154477
Conditions
Hypogonadotropic Hypogonadism
Interventions
intranasal insulin, placebo (intranasal saline)
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Odessa, Texas
Withdrawn Phase 1Phase 2 Interventional

Post Operative Delirium Study

NCT04635774
Conditions
Delirium
Interventions
Insulin, Saline
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Completed Phase 1 Interventional Accepts healthy volunteers

Dyad Oxytocin Study (DOS)

NCT02302209
Conditions
Schizophrenia, Autism Spectrum Disorder
Interventions
Oxytocin, Placebo Comparator
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes

NCT01206322
Conditions
Type 2 Diabetes Mellitus
Interventions
Intranasal insulin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dexmedetomidine vs Fentanyl for BMT

NCT00654329
Conditions
Otitis
Interventions
Saline, Fentanyl, Dexmedetomidine
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Months to 6 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
COVID-19
Interventions
theophylline, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
COVID-19 Pneumonia, COVID-19 Respiratory Infection, Pneumonia, Viral
Interventions
Cromolyn Sodium, Placebo
Drug · Other
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
El Paso, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

Intranasal Oxytocin and Enhancement of Team Cohesion

NCT02302430
Conditions
Unit Cohesion
Interventions
Oxytocin, Placebo comparator
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 28 Years
Enrollment
486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Conditions
Sedation, Conscious
Interventions
Midazolam, xylocaine, saline placebo
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Months to 7 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cooperstown, New York
Conditions
SARS-CoV-2
Interventions
Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose, NDV-HXP-S IN high dose, NDV-HXP-S IM high dose
Drug · Biological
Lead sponsor
Sean Liu
Other
Eligibility
18 Years to 59 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers

Neural Correlates of Hypoalgesia Driven by Observation

NCT03897998
Conditions
Pain, Virtual Reality, Placebo
Interventions
Naloxone, Saline
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Migraine, Facial Pain or Pressure, Headache
Interventions
Topical solution of 4% lidocaine, Saline 0.9%
Drug
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Springfield, Massachusetts
Conditions
Pain From onabotulinumtoxinA Injections
Interventions
onabotulinumtoxinA prophylaxis with Lidocaine, OnabotulinumtoxinA prophylaxis with Saline
Procedure
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Providence, Rhode Island
Completed Phase 1Phase 2 Interventional Results available

Intranasal Oxytocin for Infants With Prader-Willi Syndrome

NCT03245762
Conditions
Prader-Willi Syndrome
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
1 Week to 6 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Completed Phase 1 Interventional

Oxytocin HIV Meth Study

NCT02881177
Conditions
Amphetamine Use Disorders
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Conditions
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
Interventions
Placebo, SeVRSV Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Epistaxis, Blood Pressure
Interventions
Oxymetazoline 0.05%, Phenylephrine 0.25%, Lidocaine 1% plus epinephrine 1:100,000, Bacteriostatic 0.9% NaCL
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Posttraumatic Stress Disorder
Interventions
Neuropeptide Y
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Coronavirus Infection
Interventions
NasoVAX, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Miami, Florida • Morrow, Georgia • Chicago, Illinois + 3 more
Conditions
Post-Traumatic Stress Disorder (PTSD)
Interventions
Oxytocin nasal spray, Saline nasal spray, Brief Cognitive-Behavioral Conjoint Therapy
Drug · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Conditions
Postoperative Nausea and Vomiting
Interventions
2% Lidocaine HCl topical solution, 0.9% Sodium chloride
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Paraosmia
Interventions
Platelet-rich Plasma (PRP), Saline
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
Insulin, Placebo (Sterile diluent)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Influenza, Pandemic
Interventions
BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM
Biological
Lead sponsor
BlueWillow Biologics
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland